ArticleGut2014
Duodenal nutrient exclusion improves metabolic syndrome and stimulates villus hyperplasia.
Article in Gut, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Pooled it
- The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: a systematic review.International journal of obesity (2005) · 2015Pooled it
- Trial
- Article
- Development of a targeted oral pharmacologic duodenal exclusion therapy for the treatment of metabolic diseases.Science advances · 2025Article
- Effects of maternal hawthorn-leaf flavonoid supplementation on the intestinal development of offspring chicks.Poultry science · 2024Article
- Fantastic voyage:Comprehensive psychoneuroendocrinology · 2024Review
- Physical properties of food or bile redirection do not contribute to the intestinal adaptations after Roux-en-Y Gastric Bypass in rats.Obesity science & practice · 2023Article
- The role of glucagon after bariatric/metabolic surgery: much more than an "anti-insulin" hormone.Frontiers in endocrinology · 2023Review
- Combined non-alcoholic fatty liver disease and type 2 diabetes in severely obese patients-medium term effects of sleeve gastrectomy versus Roux-en-Y-gastric bypass on disease markers.Hepatobiliary surgery and nutrition · 2022Article
- Role of Proximal Intestinal Glucose Sensing and Metabolism in the Blood Glucose Control in Type 2 Diabetic Rats After Duodenal Jejunal Bypass Surgery.Obesity surgery · 2022Article
- Progress in treatment of type 2 diabetes by bariatric surgery.World journal of diabetes · 2021Review
- Alterations in Small Intestine and Liver Morphology, Immunolocalization of Leptin, Ghrelin and Nesfatin-1 as Well as Immunoexpression of Tight Junction Proteins in Intestinal Mucosa after Gastrectomy in Rat Model.Journal of clinical medicine · 2021Article
- The Effects of Erchen Decoction on Gut Microbiota and Lipid Metabolism Disorders in Zucker Diabetic Fatty Rats.Frontiers in pharmacology · 2021Article
- Role of Bile Acids and GLP-1 in Mediating the Metabolic Improvements of Bariatric Surgery.Gastroenterology · 2019Article
- Rethinking Bile Acid Metabolism and Signaling for Type 2 Diabetes Treatment.Current diabetes reports · 2018Review
- Recent advancements in bariatric/metabolic surgery.Annals of gastroenterological surgery · 2017Review
- Bile acids and bariatric surgery.Molecular aspects of medicine · 2017Review
- Duodenal endoluminal barrier sleeve alters gut microbiota of ZDF rats.International journal of obesity (2005) · 2017Article
- Measurement of hepatic insulin sensitivity early after the bypass of the proximal small bowel in humans.Obesity science & practice · 2017Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
18 authors at 4 institutions in 2 countries.
Funding
Abstract
objectiveSurgical interventions that prevent nutrient exposure to the duodenum are among the most successful treatments for obesity and diabetes. However, these interventions are highly invasive, irreversible and often carry significant risk. The duodenal-endoluminal sleeve (DES) is a flexible tube that acts as a barrier to nutrient-tissue interaction along the duodenum. We implanted this device in Zucker Diabetic Fatty (ZDF) rats to gain greater understanding of duodenal nutrient exclusion on glucose homeostasis.
designZDF rats were randomised to four groups: Naive, sham ad libitum, sham pair-fed, and DES implanted. Food intake, body weight (BW) and body composition were measured for 28 days postoperatively. Glucose, lipid and bile acid metabolism were evaluated, as well as histological assessment of the upper intestine.
resultsDES implantation induced a sustained decrease in BW throughout the study that was matched by pair-fed sham animals. Decreased BW resulted from loss of fat, but not lean mass. DES rats were also found to be more glucose tolerant than either ad libitum-fed or pair-fed sham controls, suggesting fat mass independent metabolic benefits. DES also reduced circulating triglyceride and glycerol levels while increasing circulating bile acids. Interestingly, DES stimulated a considerable increase in villus length throughout the upper intestine, which may contribute to metabolic improvements.
conclusionsOur preclinical results validate DES as a promising therapeutic approach to diabetes and obesity, which offers reversibility, low risk, low invasiveness and triple benefits including fat mass loss, glucose and lipid metabolism improvement which mechanistically may involve increased villus growth in the upper gut.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.